{
  "ticker": "TLX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959438",
  "id": "02959438",
  "pages": 4,
  "price_sensitive": false,
  "date": "20250618",
  "time": "0823",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250618/pdf/06kvg4tqrcnth0.pdf",
  "summary": "- **Change in Director's Interest (Dr. Christian Behrenbruch)**  \n  - **Newly Granted Securities (FY25 Remuneration):**  \n    - **166,483 PSARs** (Performance Share Appreciation Rights) at notional exercise price **$28.67** (Black-Scholes value: **$10.7997/PSAR**, total **$1.8M**).  \n    - **2,595 Deferred Share Rights (SRs)** at nil exercise price (value **$30.39/SR**, total **$78,839**).  \n  - **Existing Holdings:**  \n    - **Direct:** 553,298 ordinary shares, 100,708 options ($4.38 strike), and 357,902 PSARs (various strike prices).  \n    - **Indirect:** 20,675,000 ordinary shares (via Behrenbruch Family Trust).  \n\n**Nature of Change:** Grant under Telix Equity Incentive Plan post-AGM approval (21 May 2025).  \n\n*No material trading or capital markets impact identified.* (Routine director interest disclosure.)",
  "usage": {
    "prompt_tokens": 2012,
    "completion_tokens": 237,
    "total_tokens": 2249,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-17T22:33:49.102017"
}